Among postmenopausal women with prior hysterectomy, cessation of conjugated equine estrogen (CEE) therapy reduces the risk of stroke, and the risk of breast cancer remains reduced, according to a study to be published on April 6 in the Journal of the American Medical Association.
TUESDAY, April 5 (HealthDay News) -- Among postmenopausal women with prior hysterectomy, cessation of conjugated equine estrogen (CEE) therapy reduces the risk of stroke, and the risk of breast cancer remains reduced, according to a study to be published on April 6 in the Journal of the American Medical Association.
Andrea Z. LaCroix, Ph.D., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues examined postintervention health outcomes associated with CEE treatment in participants of the Women's Health Initiative Trial. Postmenopausal women with prior hysterectomy were randomized to receive either 0.625 mg/day CEE or placebo for 5.9 years. The trial was stopped early, but follow-up continued for women who provided written consent. Primary outcomes measured were coronary heart disease (CHD) and invasive breast cancer after an average follow-up of 10.7 years.
The investigators found that the annualized postintervention risk for CHD, and total mortality for women assigned to CEE was similar to controls (hazard ratio [HR], 0.97 and 1.00, respectively). Postintervention annualized risk for breast cancer was 0.26 percent in the CEE treatment group, compared to 0.34 percent in controls, and this persisted over the entire follow-up period (HR, 0.75 and 0.77, respectively). The increased risks of stroke, seen during the intervention phase, were not present during the postintervention phase. Risk of pulmonary embolism and hip fractures was similar to controls during the entire follow-up period.
"Several patterns of health risks and benefits seen during the intervention period were not maintained during the postintervention period, while other trends persisted," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Wyeth Ayerst, which provided the study drugs.
AbstractFull TextEditorial (subscription or payment may be required)
Related Content
Educational Tutorial: Hormone Replacement Therapy (HRT) Evidence-based Guidelines
Menopausal Symptoms Improve After Acupuncture Treatment
FDA adds boxed warning to fezolinetant for rare serious liver injury
Published: December 17th 2024 | Updated: December 17th 2024The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.
Read More
Shared genetics found between anti-Müllerian hormone and age at menopause
December 4th 2024In a recent study, an inverse relationship was discovered between anti-Müllerian hormone levels and early menopause, highlighting the need to develop interventions for fertility preservation based on genetics.
Read More